toxylact: a07aa02 smecta
The first professional lActological database in the word
Diosmectite (ATC class A07AA02) is an intestinal adsorbent used for symptomatic treatment of acute and chronic diarrhoea and functional bowel disorders; current regulatory advice is to avoid its use during breastfeeding because of concerns about trace lead impurities and lack of lactation data.hsa+4
Pharmacological class and mechanism
Diosmectite belongs to ATC class A07AA02, “intestinal adsorbents,” and is a natural aluminium–magnesium silicate clay with high surface area and adsorption capacity. It binds bacterial toxins, viruses, bile salts and excess water in the intestinal lumen, and reinforces the mucus barrier by adhering to mucopolysaccharides, thereby reducing stool liquidity and mucosal irritation.atcddd.fhi+3
Therapeutic indications and dosing
Oral diosmectite is indicated for treatment of acute watery diarrhoea in children aged ≥2 years and adults, usually as an adjunct to oral rehydration therapy, and for chronic functional diarrhoea and pain related to functional bowel disorders in adults. Typical adult dosing is 3 sachets per day for acute diarrhoea and up to 9 g/day for other gastrointestinal symptoms, while paediatric regimens use 4 sachets/day for the first 3 days followed by 2 sachets/day for 4 days, in children ≥2 years.pmc.ncbi.nlm.nih+3
Safety profile and general toxicology
Diosmectite is minimally absorbed from the gastrointestinal tract, so systemic exposure to the clay itself is expected to be negligible. The main dose‑related adverse reaction is constipation, and rare events include bezoar formation with overdose and potential interference with absorption of concomitant orally administered medicines if taken too close together.pmc.ncbi.nlm.nih+4
Concerns raised by several authorities relate to naturally occurring trace elements such as lead in clay-based products, leading to restrictions on use in young children and in pregnant or breastfeeding women as a precautionary measure. In practice, diosmectite should be avoided in patients with chronic constipation, bowel obstruction or severe abdominal pain of unknown origin, and rehydration remains the primary treatment of diarrhoea.npra+6
Lactation toxicology and clinical recommendations
No clinical pharmacokinetic or controlled safety studies of diosmectite in breastfeeding women or breastfed infants have been published, and human milk transfer data are lacking. Given its negligible gastrointestinal absorption, significant passage of the clay itself into breast milk is unlikely, but the presence of trace lead as an impurity has prompted multiple regulators and manufacturers to explicitly advise against use of Smecta (diosmectite) during breastfeeding as a precaution.drugoffice+5
In the absence of robust lactation safety data and considering the availability of alternative antidiarrhoeal options with better-characterised breastfeeding compatibility (for example, loperamide and kaolin‑pectin, which are recommended by some authorities for nursing mothers), dio smectite-containing products should generally be avoided in lactating women. If a breastfeeding mother has been inadvertently exposed, clinically relevant systemic or infant toxicity from diosmectite itself is unlikely, but theoretical lead exposure warrants monitoring of the infant for gastrointestinal or neurologic symptoms and consideration of switching to alternative therapies.breastfeedingnetwork+6
Practical use in breastfeeding women
For acute diarrhoea in breastfeeding women, oral rehydration, dietary adjustment and antidiarrhoeals with established lactation safety profiles are preferred over diosmectite. Where diosmectite is considered despite current restrictions, its use should be limited to short courses at the lowest effective dose, only after individual risk–benefit assessment and informed consent, and ideally in settings where infant follow‑up


